EXPAND AND CONSOLIDATE GLOBAL FOOTPRINT

to provide access to quality medicines at an affordable price

Konw More

About IMSDA

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

In The News

CDSCO’s Risk-Based Regulation Push at iPHEX 2026 - The Central Drugs Standard Control Organization (CDSCO) is advancing a smarter, risk-based regulatory framework aimed at simplifying compliance for Indian pharmaceutical manufacturers while strengthening drug safety oversight. The initiative was highlighted at iPHEX 2026, India’s flagship pharma export showcase, where regulators and industry leaders discussed the future of drug regulation in the country. Why Risk-Based […]
India’s PLI Bulk Drug Push: Rs 5,210 Crore Invested by June 2026 - The Indian government has confirmed that Rs 5,210 crore (approximately $625 million) has been invested under the Production Linked Incentive (PLI) scheme for Key Starting Materials (KSM), drug intermediates, and active pharmaceutical ingredients (APIs) — collectively referred to as “bulk drugs” — as of June 2026. What the PLI Scheme Covers The PLI scheme for […]
CDSCO Shifts to Smarter Risk-Based Regulation at iPHEX 2026 - ⚠️ What Buyers Should Watch The risk-based regulatory shift is a direction, not yet a fully implemented system. Buyers should keep the following in mind: No immediate change to existing compliance requirements — manufacturers still need valid WHO-GMP or Schedule M certification, CDSCO licences, and product-specific approvals. The risk-based model adjusts how regulators prioritise inspections, […]
Indian Pharma Update: iPHEX Deals, 10.7% Growth, and R&D Push - The Indian pharmaceutical sector delivered a strong trio of developments in September 2026 — the iPHEX 2026 expo generated an estimated US$4.5–5 billion in potential business discussions, the domestic market grew 10.7% in August despite a three-month volume low, and industry leaders issued a unified call for stronger R&D investment and resilient supply chains. Meanwhile, […]
Read More

Our Videos

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Konw More

Stay Connected

If you have any question,please connect us.

Connect Us

Join Us

The India Medicine Sales & Distribution Association ( IMSDA ) represents 24 leading research-based Indian pharmaceutical companies. IMSDA plays the role of a catalyst role in shaping policy framework to unlock and unleash the potential of the Indian pharmaceutical industry in line with the national priorities

Join Us